CTOs on the Move


 
Penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. We design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. Today we have over 1,300 employees with sales operations in North America, Europe, Latin America, Australia and Asia. Members of the Penumbra team agree that this is where their work has meaning -- we are transforming the treatment of some of the world`s most devastating conditions. Penumbra is ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

MJW Corporation Inc

MJW Corporation Inc is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scandius BioMedical

Scandius BioMedical is a Littleton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Athera

Athera Incorporated is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Companion Medical

Companion Medical is a leader in the development of advanced technology to improve diabetes care. Companion`s InPen system is available in the U.S. and is the only FDA-cleared, smart insulin pen paired with an integrated diabetes management app.

EnteroMedics

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. vBloc Therapy is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.* *Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.